Bio Green Med Solution, Inc. (BGMS)vsRegeneron Pharmaceuticals Inc (REGN)
BGMS
Bio Green Med Solution, Inc.
$1.50
+41.51%
HEALTHCARE · Cap: $5.85M
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.11%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 978234% more annual revenue ($14.92B vs $1.52M). REGN leads profitability with a 29.6% profit margin vs -204.2%. BGMS trades at a lower P/E of 0.2x. REGN earns a higher WallStSmart Score of 64/100 (C+).
BGMS
Hold45
out of 100
Grade: D
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BGMS.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 710.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -46.1% — below average capital efficiency
Negative free cash flow — burning cash
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : BGMS
The strongest argument for BGMS centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 710.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : BGMS
The primary concerns for BGMS are EPS Growth, Market Cap, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
BGMS profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.30 — expect wider price swings.
BGMS is growing revenue faster at 710.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 45/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bio Green Med Solution, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. The company is headquartered in Kuala Lumpur, Malaysia.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?